Anatomical main group
L – ANTINEOPLASTISCHE UND IMMUNMODULIERENDE MITTEL
565Decisions
913Patient groups
Added benefit by patient group
- Major8
- Considerable122
- Minor101
- Non-quantifiable84
- Not proven593
- Lesser benefit5
Subgroups
- L01 ANTINEOPLASTISCHE MITTEL 432 decisions
- L02 ENDOKRINE THERAPIE 14 decisions
- L03 IMMUNSTIMULANZIEN 1 decision
- L04 IMMUNSUPPRESSIVA 118 decisions
Decisions, newest first
- 2026-10-01BlenrepBelantamab-MafodotinNot proven: 2 of 2 patient groups
- 2026-10-01BlenrepBelantamab-MafodotinNon-quantifiable: 1 of 4 patient groupsNot proven: 3 of 4 patient groups
- 2026-10-01ZynyzRetifanlimabMinor
- 2026-10-01ZynyzRetifanlimabNon-quantifiable
- 2026-09-03UpliznaInebilizumabNot proven: 2 of 2 patient groups
- 2026-09-03UpliznaInebilizumabNon-quantifiable
- 2026-09-03AkeegaNiraparib/AbirateronacetatNot proven: 2 of 2 patient groups
- 2026-08-20TepezzaTeprotumumabNot proven: 3 of 3 patient groups
- 2026-08-20TibsovoIvosidenibNot proven
- 2026-08-20TibsovoIvosidenibNot proven
- 2026-08-20VerzeniosAbemaciclibMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2026-08-06AspaveliPegcetacoplanNon-quantifiable
- 2026-08-06AspaveliPegcetacoplanNon-quantifiable
- 2026-08-06KoselugoSelumetinibNon-quantifiable
- 2026-08-06ZiiheraZanidatamabNon-quantifiable
- 2026-07-16ElahereMirvetuximab SoravtansinConsiderable
- 2026-07-02LoqtorziToripalimabNot proven: 2 of 2 patient groups
- 2026-07-02LoqtorziToripalimabNot proven
- 2026-07-02MinjuviTafasitamabNon-quantifiable: 2 of 2 patient groups
- 2026-06-18TremfyaGuselkumabNot proven
- 2026-06-18RetsevmoSelpercatinibNot proven: 2 of 2 patient groups
- 2026-06-18ImaavyNipocalimabNot proven: 4 of 4 patient groups
- 2026-06-04FabhaltaIptacopanNot proven
- 2026-06-04FabhaltaIptacopanNot proven: 2 of 2 patient groups
- 2026-06-04OpdivoNivolumabConsiderable
- 2026-06-04BreyanziLisocabtagen maraleucelNot proven
- 2026-06-04LibtayoCemiplimabNon-quantifiable
- 2026-05-21ScemblixAsciminibConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2026-05-21KeytrudaPembrolizumabMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2026-05-07KoselugoSelumetinibMinor
- 2026-05-07KoselugoSelumetinibNon-quantifiable
- 2026-05-07AyvakytAvapritinibMinor
- 2026-05-07VoranigoVorasidenibNon-quantifiable
- 2026-04-16AyvakytAvapritinibNot proven
- 2026-04-16AyvakytAvapritinibNot proven
- 2026-04-16OmjjaraMomelotinibNot proven: 2 of 2 patient groups
- 2026-04-16RomvimzaVimseltinibConsiderable
- 2026-04-02OgsiveoNirogacestatMinor
- 2026-03-19TevimbraTislelizumabNot proven
- 2026-03-19TevimbraTislelizumabNot proven
- 2026-03-19TevimbraTislelizumabNot proven
- 2026-03-19TaltzIxekizumabNot proven
- 2026-03-19TaltzIxekizumabNot proven
- 2026-03-19EnhertuTrastuzumab deruxtecanMinor
- 2026-03-19LynozyficLinvoseltamabNot proven: 2 of 2 patient groups
- 2026-03-19EzmeklyMirdametinibNon-quantifiable
- 2026-03-05TavneosAvacopanNot proven
- 2026-02-19DarzalexDaratumumabMinor
- 2026-02-19DarzalexDaratumumabMinor
- 2026-02-19ItovebiInavolisibConsiderable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2026-02-19TivdakTisotumab VedotinNot proven: 3 of 3 patient groups
- 2026-02-19SarclisaIsatuximabNot proven
- 2026-02-19NubeqaDarolutamidNot proven
- 2026-01-22VyvgartEfgartigimod alfaNot proven
- 2026-01-22ImfinziDurvalumabConsiderable
- 2026-01-22ImfinziDurvalumabNot proven
- 2026-01-22OrdsponoOdronextamabNot proven
- 2026-01-22OrdsponoOdronextamabNot proven: 2 of 2 patient groups
- 2026-01-22ImfinziDurvalumabMinor
- 2025-12-18OpdivoNivolumabMinor
- 2025-12-18CalquenceAcalabrutinibNot proven
- 2025-12-18CalquenceAcalabrutinibNot proven: 2 of 2 patient groups
- 2025-12-18CalquenceAcalabrutinibNot proven
- 2025-12-18OpdivoNivolumabNot proven
- 2025-12-18CalquenceAcalabrutinibNot proven
- 2025-12-04OpdivoNivolumabNot proven
- 2025-12-04OpdivoNivolumabNot proven: 2 of 2 patient groups
- 2025-11-20DatrowayDatopotamab deruxtecanNot proven: 3 of 3 patient groups
- 2025-11-20TremfyaGuselkumabNot proven: 2 of 2 patient groups
- 2025-11-20TremfyaGuselkumabMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2025-11-20RetsevmoSelpercatinibMajor
- 2025-11-20ScemblixAsciminibMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2025-11-06RinvoqUpadacitinibMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2025-11-06ColumviGlofitamabNot proven: 3 of 3 patient groups
- 2025-11-06ColumviGlofitamabNot proven: 2 of 2 patient groups
- 2025-10-16KeytrudaPembrolizumabNot proven
- 2025-10-16HetroniflySerplulimabNon-quantifiable
- 2025-10-16EnhertuTrastuzumab deruxtecanMinor
- 2025-10-16AugtyroRepotrectinibNot proven: 2 of 2 patient groups
- 2025-10-16AugtyroRepotrectinibNot proven: 3 of 3 patient groups
- 2025-10-02JaypircaPirtobrutinibMinor: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2025-10-02BreyanziLisocabtagen maraleucelNot proven
- 2025-09-18WeliregBelzutifanNot proven
- 2025-09-18WeliregBelzutifanMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2025-09-04OmvohMirikizumabNot proven: 2 of 2 patient groups
- 2025-08-21BlincytoBlinatumomabConsiderable
- 2025-08-21InrebicFedratinibNon-quantifiable
- 2025-08-21DarzalexDaratumumabConsiderable
- 2025-08-21BlincytoBlinatumomabNon-quantifiable
- 2025-08-21BlincytoBlinatumomabNon-quantifiable
- 2025-08-07JemperliDostarlimabNot proven
- 2025-08-07SarclisaIsatuximabMinor
- 2025-08-07JaypircaPirtobrutinibNot proven
- 2025-08-07KevzaraSarilumabNot proven: 2 of 2 patient groups
- 2025-08-07OfevNintedanibNot proven
- 2025-08-07OfevNintedanibNot proven
- 2025-08-07KevzaraSarilumabNot proven
- 2025-07-17RybrevantAmivantamabNot proven
- 2025-07-17LazcluzeLazertinibMinor
- 2025-07-17RybrevantAmivantamabNot proven: 2 of 2 patient groups
- 2025-07-17RybrevantAmivantamabMinor
- 2025-07-03TagrissoOsimertinibNot proven: 2 of 2 patient groups
- 2025-06-18TevimbraTislelizumabNot proven: 2 of 2 patient groups
- 2025-06-18TevimbraTislelizumabNot proven: 2 of 2 patient groups
- 2025-06-18TevimbraTislelizumabNot proven
- 2025-06-18BalversaErdafitinibNot proven: 3 of 3 patient groups
- 2025-06-18TevimbraTislelizumabNot proven
- 2025-06-18TevimbraTislelizumabNot proven: 2 of 2 patient groups
- 2025-06-18TevimbraTislelizumabNot proven
- 2025-06-05KisqaliRibociclibNot proven: 3 of 3 patient groups
- 2025-05-15DarzalexDaratumumabNot proven
- 2025-05-15OtezlaApremilastNot proven
- 2025-05-15KeytrudaPembrolizumabNot proven: 2 of 2 patient groups
- 2025-05-15KeytrudaPembrolizumabNon-quantifiable
- 2025-05-15CarvyktiCiltacabtagen autoleucelConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2025-04-17TepkinlyEpcoritamabNot proven: 2 of 2 patient groups
- 2025-04-17VyloyZolbetuximabMinor
- 2025-04-03TruqapCapivasertibConsiderable: 1 of 4 patient groupsNot proven: 3 of 4 patient groups
- 2025-04-03PadcevEnfortumab VedotinConsiderable: 1 of 2 patient groupsNon-quantifiable: 1 of 2 patient groups
- 2025-04-03KeytrudaPembrolizumabConsiderable: 1 of 3 patient groupsNon-quantifiable: 1 of 3 patient groupsNot proven: 1 of 3 patient groups
- 2025-03-20TecentriqAtezolizumabConsiderable
- 2025-03-20BraftoviEncorafenibNot proven: 3 of 3 patient groups
- 2025-03-20MektoviBinimetinibNot proven: 3 of 3 patient groups
- 2025-03-20TecentriqAtezolizumabMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2025-03-20KeytrudaPembrolizumabMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2025-03-06TepkinlyEpcoritamabNot proven
- 2025-03-06PiaSkyCrovalimabNot proven: 2 of 2 patient groups
- 2025-02-20LynparzaOlaparibConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2025-02-20ImfinziDurvalumabConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2025-02-20ImfinziDurvalumabNot proven
- 2025-02-20SkyriziRisankizumabNot proven: 2 of 2 patient groups
- 2025-02-06TagrissoOsimertinibNot proven
- 2025-01-16AlecensaAlectinibMajor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2025-01-16FruzaqlaFruquintinibMinor
- 2024-12-19YescartaAxicabtagen-CiloleucelMinor
- 2024-12-19TagrissoOsimertinibMajor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2024-12-19OpdivoNivolumabNot proven
- 2024-11-22VoydeyaDanicopanNon-quantifiable
- 2024-11-22LytgobiFutibatinibNot proven
- 2024-11-22BimzelxBimekizumabNot proven
- 2024-11-22AspaveliPegcetacoplanNon-quantifiable
- 2024-11-07RetsevmoSelpercatinibNot proven
- 2024-11-07RetsevmoSelpercatinibNot proven: 2 of 2 patient groups
- 2024-10-17KeytrudaPembrolizumabNot proven: 2 of 2 patient groups
- 2024-10-17KeytrudaPembrolizumabNot proven
- 2024-10-17SpexotrasTrametinibConsiderable: 1 of 3 patient groupsNon-quantifiable: 2 of 3 patient groups
- 2024-10-17FinleeDabrafenibConsiderable: 1 of 3 patient groupsNon-quantifiable: 2 of 3 patient groups
- 2024-10-02VelsipityEtrasimodNot proven: 2 of 2 patient groups
- 2024-09-19AbecmaIdecabtagen vicleucelNot proven
- 2024-09-19VyvgartEfgartigimod alfaNot proven
- 2024-08-15RystiggoRozanolixizumabConsiderable: 1 of 2 patient groupsNon-quantifiable: 1 of 2 patient groups
- 2024-08-15ZilbrysqZilucoplanNot proven
- 2024-08-15TalzennaTalazoparibNot proven: 2 of 3 patient groupsLesser benefit: 1 of 3 patient groups
- 2024-08-01VanflytaQuizartinibNot proven
- 2024-08-01BriumviUblituximabMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2024-07-04ElrexfioElranatamabNot proven: 2 of 2 patient groups
- 2024-06-20KeytrudaPembrolizumabMinor
- 2024-06-20KeytrudaPembrolizumabNot proven
- 2024-06-20KeytrudaPembrolizumabNot proven
- 2024-06-20PolivyPolatuzumab VedotinNot proven
- 2024-06-20PolivyPolatuzumab VedotinNot proven: 3 of 3 patient groups
- 2024-06-20JemperliDostarlimabMajor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2024-06-06RubracaRucaparibNot proven
- 2024-06-06BrukinsaZanubrutinibNot proven
- 2024-05-16DarzalexDaratumumabConsiderable
- 2024-05-16KimmtrakTebentafuspConsiderable
- 2024-05-16EnhertuTrastuzumab deruxtecanNot proven: 2 of 2 patient groups
- 2024-05-02OlumiantBaricitinibNot proven
- 2024-05-02OlumiantBaricitinibNot proven: 2 of 2 patient groups
- 2024-05-02AkeegaNiraparib/AbirateronacetatConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2024-05-02RydaptMidostaurinNot proven
- 2024-05-02RydaptMidostaurinNot proven
- 2024-05-02OlumiantBaricitinibNot proven: 3 of 3 patient groups
- 2024-05-02OlumiantBaricitinibNot proven: 2 of 2 patient groups
- 2024-05-02OrserduElacestrantConsiderable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2024-04-04TepkinlyEpcoritamabNon-quantifiable
- 2024-03-21OpdivoNivolumabNot proven
- 2024-03-21HyftorSirolimusNon-quantifiable
- 2024-03-07TalveyTalquetamabNon-quantifiable
- 2024-02-15TecvayliTeclistamabNot proven
- 2024-02-15KymriahTisagenlecleucelNon-quantifiable
- 2024-02-15KymriahTisagenlecleucelNon-quantifiable
- 2024-02-15LonsurfTrifluridin/TipiracilConsiderable
- 2024-02-15TrodelvySacituzumab govitecanConsiderable
- 2024-02-06RozlytrekEntrectinibNot proven
- 2024-02-01OpdivoNivolumabNon-quantifiable
- 2024-01-18OmvohMirikizumabNot proven: 2 of 2 patient groups
- 2024-01-18TecfideraDimethylfumaratNot proven
- 2023-12-21BimzelxBimekizumabNot proven: 2 of 2 patient groups
- 2023-12-21OpdivoNivolumabNot proven
- 2023-12-21OpdivoNivolumabNot proven: 2 of 2 patient groups
- 2023-12-21BimzelxBimekizumabNot proven: 2 of 2 patient groups
- 2023-12-21BimzelxBimekizumabNot proven: 2 of 2 patient groups
- 2023-12-21YescartaAxicabtagen-CiloleucelNot proven
- 2023-12-07UltomirisRavulizumabNot proven
- 2023-12-07CosentyxSecukinumabNot proven
- 2023-11-16BreyanziLisocabtagen maraleucelConsiderable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2023-11-02Zynlonta Loncastuximab tesirinNot proven: 2 of 2 patient groups
- 2023-10-19LibtayoCemiplimabNot proven: 2 of 2 patient groups
- 2023-10-19LibtayoCemiplimabConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2023-10-19RinvoqUpadacitinibNot proven: 2 of 2 patient groups
- 2023-10-05EbvalloTabelecleucelNon-quantifiable
- 2023-10-05ImfinziDurvalumabMinor
- 2023-10-05ImfinziDurvalumabNot proven: 2 of 2 patient groups
- 2023-10-05ImfinziDurvalumabNot proven: 2 of 2 patient groups
- 2023-10-05Tremelimumab AstraZenecaTremelimumabNot proven: 2 of 2 patient groups
- 2023-10-05ImjudoTremelimumabNot proven: 2 of 2 patient groups
- 2023-10-05SotyktuDeucravacitinibNot proven: 2 of 2 patient groups
- 2023-09-21RubracaRucaparibNot proven
- 2023-09-21NubeqaDarolutamidConsiderable
- 2023-09-21LynparzaOlaparibNot proven
- 2023-08-17LupkynisVoclosporinNot proven
- 2023-08-03LumykrasSotorasibNon-quantifiable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2023-07-20ImbruvicaIbrutinibNot proven: 2 of 2 patient groups
- 2023-07-20EnhertuTrastuzumab deruxtecanConsiderable
- 2023-07-20SpevigoSpesolimabNot proven
- 2023-07-20EnhertuTrastuzumab deruxtecanNot proven
- 2023-07-06LynparzaOlaparibConsiderable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2023-06-15VerzeniosAbemaciclibMinor
- 2023-06-15EnjaymoSutimlimabMinor
- 2023-06-15SkyriziRisankizumabMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2023-06-15BrukinsaZanubrutinibMinor: 1 of 4 patient groupsNot proven: 3 of 4 patient groups
- 2023-06-15BrukinsaZanubrutinibNot proven
- 2023-06-15BrukinsaZanubrutinibMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2023-04-20LynparzaOlaparibConsiderable
- 2023-04-20UltomirisRavulizumabNot proven
- 2023-04-06OrgovyxRelugolixNot proven: 5 of 5 patient groups
- 2023-04-06BreyanziLisocabtagen maraleucelNot proven
- 2023-03-16TecartusBrexucabtagen autoleucelNon-quantifiable
- 2023-03-16PhesgoPertuzumab/TrastuzumabMinor
- 2023-03-16PerjetaPertuzumabMinor
- 2023-03-16PepaxtiMelphalanflufenamidNot proven
- 2023-03-16ScemblixAsciminibMinor
- 2023-03-16NexpovioSelinexorNot proven
- 2023-03-16NexpovioSelinexorNot proven
- 2023-02-16RinvoqUpadacitinibNot proven: 2 of 2 patient groups
- 2023-02-16LynparzaOlaparibMinor
- 2023-02-16RinvoqUpadacitinibNot proven: 2 of 2 patient groups
- 2023-02-02TabrectaCapmatinibNot proven: 3 of 3 patient groups
- 2023-02-02KeytrudaPembrolizumabConsiderable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2023-02-02EnhertuTrastuzumab deruxtecanConsiderable
- 2023-02-02EnhertuTrastuzumab deruxtecanNon-quantifiable
- 2023-01-19UpliznaInebilizumabNot proven
- 2023-01-19KeytrudaPembrolizumabNot proven
- 2023-01-19KeytrudaPembrolizumabNon-quantifiable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2023-01-19KeytrudaPembrolizumabNot proven
- 2023-01-19KeytrudaPembrolizumabNot proven
- 2023-01-19KeytrudaPembrolizumabNon-quantifiable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2023-01-19KeytrudaPembrolizumabNot proven
- 2023-01-19KeytrudaPembrolizumabNot proven
- 2023-01-19KeytrudaPembrolizumabMinor
- 2023-01-05CosentyxSecukinumabNot proven
- 2023-01-05CosentyxSecukinumabNot proven
- 2022-12-15IbrancePalbociclibNot proven
- 2022-12-15LunsumioMosunetuzumabNon-quantifiable
- 2022-12-01KymriahTisagenlecleucelNon-quantifiable
- 2022-12-01Cabometyx CabozantinibNot proven
- 2022-12-01PadcevEnfortumab VedotinConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2022-11-03YescartaAxicabtagen-CiloleucelNon-quantifiable: 2 of 2 patient groups
- 2022-10-20OpdivoNivolumabConsiderable
- 2022-10-20OpdivoNivolumabConsiderable
- 2022-10-20OpdivoNivolumabNot proven
- 2022-10-20VerzeniosAbemaciclibNot proven
- 2022-10-06SaphneloAnifrolumabNot proven
- 2022-09-15AspaveliPegcetacoplanNon-quantifiable
- 2022-09-15DarzalexDaratumumabConsiderable
- 2022-09-01EntyvioVedolizumabNot proven
- 2022-09-01LorviquaLorlatinibNot proven
- 2022-09-01TepmetkoTepotinibNot proven: 3 of 3 patient groups
- 2022-08-04LumykrasSotorasibNot proven
- 2022-08-04TavneosAvacopanMinor
- 2022-07-21CopiktraDuvelisibNot proven
- 2022-07-21CopiktraDuvelisibNot proven: 4 of 4 patient groups
- 2022-07-07KeytrudaPembrolizumabNot proven: 2 of 2 patient groups
- 2022-07-07LenvimaLenvatinibConsiderable
- 2022-07-07KisplyxLenvatinibNot proven: 2 of 2 patient groups
- 2022-07-07RybrevantAmivantamabNot proven: 2 of 2 patient groups
- 2022-06-16QinlockRipretinibMajor
- 2022-06-16AbecmaIdecabtagen vicleucelNon-quantifiable
- 2022-06-16ZeposiaOzanimodNot proven: 2 of 2 patient groups
- 2022-06-16XeljanzTofacitinibNot proven: 2 of 2 patient groups
- 2022-06-16BrukinsaZanubrutinibNot proven
- 2022-06-16GavretoPralsetinibNot proven: 5 of 5 patient groups
- 2022-05-19PonvoryPonesimodMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2022-05-19OpdivoNivolumabConsiderable
- 2022-05-19VerzeniosAbemaciclibMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2022-05-19TrodelvySacituzumab govitecanMajor
- 2022-05-19SkyriziRisankizumabNot proven: 2 of 2 patient groups
- 2022-05-19JyselecaFilgotinibNot proven: 2 of 2 patient groups
- 2022-05-05KeytrudaPembrolizumabConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2022-05-05KeytrudaPembrolizumabConsiderable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2022-04-21NinlaroIxazomibNon-quantifiable
- 2022-03-18CaprelsaVandetanibNot proven
- 2022-03-18DarzalexDaratumumabConsiderable
- 2022-03-18UltomirisRavulizumabNot proven: 2 of 2 patient groups
- 2022-03-03MinjuviTafasitamabNon-quantifiable
- 2022-03-03XeljanzTofacitinibNot proven: 5 of 5 patient groups
- 2022-03-03BimzelxBimekizumabMinor: 2 of 2 patient groups
- 2022-02-17XeljanzTofacitinibNot proven: 6 of 6 patient groups
- 2022-02-17RinvoqUpadacitinibConsiderable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2022-02-03DarzalexDaratumumabMinor: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2022-01-20OpdivoNivolumabNot proven
- 2022-01-20DarzalexDaratumumabNot proven
- 2022-01-20LibtayoCemiplimabMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2022-01-20LibtayoCemiplimabNot proven
- 2022-01-20BlincytoBlinatumomabMajor
- 2022-01-20AubagioTeriflunomidNot proven
- 2022-01-06EnspryngSatralizumabMinor
- 2021-12-16AdcetrisBrentuximab VedotinMinor
- 2021-12-16EmplicitiElotuzumabConsiderable
- 2021-12-16OpdivoNivolumabConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2021-12-16CometriqCabozantinibNon-quantifiable
- 2021-12-02PonvoryPonesimodNot proven
- 2021-12-02JemperliDostarlimabNot proven
- 2021-12-02VenclyxtoVenetoclaxConsiderable
- 2021-12-02ElzonrisTagraxofuspNon-quantifiable
- 2021-11-19XtandiEnzalutamidNot proven
- 2021-11-19BosulifBosutinibNot proven
- 2021-11-19TecentriqAtezolizumabNot proven: 2 of 2 patient groups
- 2021-11-04SarclisaIsatuximabNot proven
- 2021-11-04SarclisaIsatuximabMinor
- 2021-11-04GazyvaroObinutuzumabNot proven
- 2021-11-04GazyvaroObinutuzumabNot proven
- 2021-11-04GazyvaroObinutuzumabNot proven
- 2021-10-21OpdivoNivolumabNot proven: 2 of 2 patient groups
- 2021-10-21Cabometyx CabozantinibNot proven: 2 of 2 patient groups
- 2021-10-07PemazyrePemigatinibNon-quantifiable
- 2021-09-16OpdivoNivolumabConsiderable
- 2021-09-16KeytrudaPembrolizumabNot proven
- 2021-09-16KeytrudaPembrolizumabMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2021-09-16KeytrudaPembrolizumabConsiderable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2021-09-02RetsevmoSelpercatinibNot proven
- 2021-09-02RetsevmoSelpercatinibNot proven
- 2021-09-02RetsevmoSelpercatinibNot proven: 3 of 3 patient groups
- 2021-09-02TukysaTucatinibConsiderable
- 2021-09-02InrebicFedratinibNon-quantifiable
- 2021-09-02IdefirixImlifidaseNon-quantifiable
- 2021-08-19BavencioAvelumabConsiderable
- 2021-08-05TecartusBrexucabtagen autoleucelNon-quantifiable
- 2021-08-05CalquenceAcalabrutinibConsiderable: 1 of 5 patient groupsMinor: 1 of 5 patient groupsNot proven: 3 of 5 patient groups
- 2021-07-15ZejulaNiraparibNot proven
- 2021-07-15RinvoqUpadacitinibNot proven: 2 of 2 patient groups
- 2021-07-15RinvoqUpadacitinibConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2021-07-15PhesgoPertuzumab/TrastuzumabNot proven
- 2021-07-15PhesgoPertuzumab/TrastuzumabNot proven
- 2021-07-15BlincytoBlinatumomabNon-quantifiable
- 2021-07-15KyprolisCarfilzomibNot proven
- 2021-07-01KisplyxLenvatinibNot proven
- 2021-07-01OpdivoNivolumabMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2021-06-03YervoyIpilimumabMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2021-06-03OpdivoNivolumabMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2021-06-03LynparzaOlaparibConsiderable
- 2021-06-03CalquenceAcalabrutinibMinor: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2021-06-03CalquenceAcalabrutinibMinor: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2021-06-03LynparzaOlaparibNot proven
- 2021-05-20TremfyaGuselkumabNot proven: 2 of 2 patient groups
- 2021-05-20ZejulaNiraparibNot proven
- 2021-05-20TecentriqAtezolizumabConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2021-05-06OlumiantBaricitinibNot proven
- 2021-04-15JyselecaFilgotinibMinor: 1 of 6 patient groupsNot proven: 5 of 6 patient groups
- 2021-04-01ImbruvicaIbrutinibConsiderable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2021-04-01ImfinziDurvalumabMinor
- 2021-02-18RozlytrekEntrectinibNot proven
- 2021-02-18CosentyxSecukinumabNot proven
- 2021-02-18CosentyxSecukinumabMinor
- 2021-02-18CosentyxSecukinumabMinor: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2021-02-18PiqrayAlpelisibNot proven: 3 of 5 patient groupsLesser benefit: 2 of 5 patient groups
- 2021-02-18RozlytrekEntrectinibNot proven
- 2021-02-18DaurismoGlasdegibConsiderable
- 2021-02-04OfevNintedanibMinor
- 2021-02-04OfevNintedanibNot proven
- 2021-01-21TaltzIxekizumabNot proven
- 2021-01-21TaltzIxekizumabNot proven: 3 of 3 patient groups
- 2021-01-21UltomirisRavulizumabNot proven
- 2021-01-07ZeposiaOzanimodMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2020-12-17BraftoviEncorafenibConsiderable
- 2020-12-03PoteligeoMogamulizumabNon-quantifiable
- 2020-11-20IclusigPonatinibNon-quantifiable
- 2020-11-20IclusigPonatinibNon-quantifiable
- 2020-11-20TalzennaTalazoparibConsiderable
- 2020-11-05XtandiEnzalutamidMinor
- 2020-11-05OtezlaApremilastNot proven
- 2020-10-15NubeqaDarolutamidConsiderable
- 2020-10-15VenclyxtoVenetoclaxNot proven: 3 of 3 patient groups
- 2020-10-15AlunbrigBrigatinibConsiderable: 1 of 2 patient groupsMinor: 1 of 2 patient groups
- 2020-10-01ErleadaApalutamidMinor
- 2020-10-01LonsurfTrifluridin/TipiracilMinor
- 2020-10-01BavencioAvelumabNot proven
- 2020-09-03VerzeniosAbemaciclibNot proven
- 2020-08-20ErleadaApalutamidNot proven
- 2020-08-20DarzalexDaratumumabNon-quantifiable
- 2020-08-20DarzalexDaratumumabMinor
- 2020-08-20KisqaliRibociclibMinor: 2 of 2 patient groups
- 2020-08-20KisqaliRibociclibMinor
- 2020-08-20CyramzaRamucirumabNot proven: 2 of 2 patient groups
- 2020-08-20MayzentSiponimodNot proven: 2 of 2 patient groups
- 2020-07-16RinvoqUpadacitinibConsiderable: 1 of 7 patient groupsMinor: 1 of 7 patient groupsNot proven: 5 of 7 patient groups
- 2020-07-02KadcylaTrastuzumab EmtansinMinor
- 2020-05-14BenlystaBelimumabNon-quantifiable
- 2020-05-14KeytrudaPembrolizumabConsiderable
- 2020-05-14KeytrudaPembrolizumabConsiderable: 2 of 2 patient groups
- 2020-05-14BavencioAvelumabConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2020-05-14NerlynxNeratinibMinor
- 2020-05-14KeytrudaPembrolizumabMinor
- 2020-05-14XospataGilteritinibConsiderable
- 2020-04-02TecentriqAtezolizumabMinor
- 2020-04-02LonsurfTrifluridin/TipiracilMinor
- 2020-04-02TecentriqAtezolizumabNot proven: 2 of 2 patient groups
- 2020-04-02TecentriqAtezolizumabNon-quantifiable
- 2020-04-02VitrakviLarotrectinibNot proven
- 2020-04-02TecentriqAtezolizumabNot proven: 2 of 2 patient groups
- 2020-03-05BesremiRopeginterferon alfa-2bNot proven: 2 of 2 patient groups
- 2020-02-20CyramzaRamucirumabMinor
- 2020-02-20ImbruvicaIbrutinibMinor: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2020-02-20ImbruvicaIbrutinibNot proven
- 2020-02-06LibtayoCemiplimabNot proven: 2 of 2 patient groups
- 2020-02-06UltomirisRavulizumabNot proven: 2 of 2 patient groups
- 2020-01-16LynparzaOlaparibMinor
- 2019-12-05Imnovid PomalidomidNot proven
- 2019-11-22LorviquaLorlatinibNot proven: 2 of 2 patient groups
- 2019-11-22SkyriziRisankizumabConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2019-10-17VizimproDacomitinibNot proven: 2 of 2 patient groups
- 2019-10-17OfevNintedanibConsiderable
- 2019-09-19KeytrudaPembrolizumabConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2019-09-19KeytrudaPembrolizumabNon-quantifiable: 2 of 2 patient groups
- 2019-09-19KeytrudaPembrolizumabNon-quantifiable
- 2019-09-05AdcetrisBrentuximab VedotinNon-quantifiable
- 2019-08-15YervoyIpilimumabConsiderable: 2 of 2 patient groups
- 2019-08-15OpdivoNivolumabConsiderable: 2 of 2 patient groups
- 2019-08-15BlincytoBlinatumomabNon-quantifiable
- 2019-08-15LenvimaLenvatinibNot proven
- 2019-08-15BlincytoBlinatumomabNon-quantifiable
- 2019-07-04AlunbrigBrigatinibNot proven
- 2019-07-04KisqaliRibociclibNot proven: 5 of 5 patient groups
- 2019-06-20TecentriqAtezolizumabNot proven
- 2019-06-20GilenyaFingolimodNon-quantifiable: 2 of 4 patient groupsNot proven: 2 of 4 patient groups
- 2019-06-06Cabometyx CabozantinibMinor
- 2019-05-16VenclyxtoVenetoclaxNot proven: 2 of 2 patient groups
- 2019-05-16VenclyxtoVenetoclaxMinor: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2019-05-02IlumetriTildrakizumabNot proven: 2 of 2 patient groups
- 2019-05-02VerzeniosAbemaciclibNot proven
- 2019-05-02VerzeniosAbemaciclibNot proven: 3 of 3 patient groups
- 2019-04-04ImfinziDurvalumabConsiderable
- 2019-04-04KeytrudaPembrolizumabNot proven
- 2019-03-22IbrancePalbociclibNot proven: 2 of 2 patient groups
- 2019-03-22BraftoviEncorafenibNot proven: 2 of 2 patient groups
- 2019-03-22MektoviBinimetinibNot proven: 2 of 2 patient groups
- 2019-03-22MekinistTrametinibConsiderable
- 2019-03-22TafinlarDabrafenibConsiderable
- 2019-03-22Vyxeos liposomalDaunorubicin/CytarabinConsiderable
- 2019-03-22LenvimaLenvatinibNot proven: 2 of 2 patient groups
- 2019-02-21MylotargGemtuzumab OzogamicinNon-quantifiable
- 2019-02-21BosulifBosutinibNot proven: 2 of 2 patient groups
- 2019-02-21XeljanzTofacitinibNot proven: 2 of 2 patient groups
- 2019-02-21XeljanzTofacitinibMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2019-01-17TagrissoOsimertinibConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2018-12-20YervoyIpilimumabNot proven: 2 of 3 patient groupsLesser benefit: 1 of 3 patient groups
- 2018-12-20OpdivoNivolumabLesser benefit
- 2018-12-06Cabometyx CabozantinibNot proven: 2 of 2 patient groups
- 2018-12-06LynparzaOlaparibMinor
- 2018-11-22AlofiselDarvadstrocelNon-quantifiable
- 2018-08-16TaltzIxekizumabMinor: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2018-08-02YervoyIpilimumabNot proven
- 2018-08-02OdomzoSonidegibNot proven
- 2018-08-02OcrevusOcrelizumabMinor: 2 of 3 patient groupsNot proven: 1 of 3 patient groups
- 2018-07-05AdcetrisBrentuximab VedotinMinor
- 2018-06-21AlecensaAlectinibNon-quantifiable
- 2018-06-07ZytigaAbirateronacetatConsiderable
- 2018-05-17TremfyaGuselkumabConsiderable: 2 of 2 patient groups
- 2018-05-17MavencladCladribinNot proven: 2 of 2 patient groups
- 2018-04-19FotivdaTivozanibNot proven: 3 of 3 patient groups
- 2018-04-05Cabometyx CabozantinibMinor
- 2018-03-16TecentriqAtezolizumabMinor
- 2018-03-16TecentriqAtezolizumabConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2018-03-16KeytrudaPembrolizumabConsiderable
- 2018-03-01KyntheumBrodalumabNon-quantifiable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2018-02-15DarzalexDaratumumabNot proven
- 2018-02-15KyprolisCarfilzomibConsiderable: 2 of 2 patient groups
- 2018-02-15KevzaraSarilumabConsiderable: 1 of 4 patient groupsNot proven: 3 of 4 patient groups
- 2018-02-01ZykadiaCeritinibNot proven
- 2018-01-18BesponsaInotuzumab ozogamicinMinor
- 2017-12-21OpdivoNivolumabNot proven
- 2017-12-07BlincytoBlinatumomabConsiderable
- 2017-11-17OpdivoNivolumabConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2017-11-17KeytrudaPembrolizumabNot proven
- 2017-10-19TafinlarDabrafenibNot proven: 3 of 3 patient groups
- 2017-10-19MekinistTrametinibNot proven: 3 of 3 patient groups
- 2017-10-19TagrissoOsimertinibConsiderable
- 2017-10-19AlecensaAlectinibMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2017-09-21OlumiantBaricitinibNot proven: 4 of 4 patient groups
- 2017-09-21InlytaAxitinibMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2017-08-17CosentyxSecukinumabConsiderable
- 2017-08-17TaltzIxekizumabConsiderable: 1 of 2 patient groupsMinor: 1 of 2 patient groups
- 2017-08-03KeytrudaPembrolizumabConsiderable
- 2017-07-06CaprelsaVandetanibNon-quantifiable
- 2017-06-15OpdivoNivolumabNot proven
- 2017-05-18IbrancePalbociclibNot proven
- 2017-03-16ImbruvicaIbrutinibConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2017-03-16XalkoriCrizotinibNot proven: 3 of 3 patient groups
- 2017-03-16ZykadiaCeritinibConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2017-03-16ZydeligIdelalisibNon-quantifiable: 1 of 4 patient groupsNot proven: 3 of 4 patient groups
- 2017-02-02KeytrudaPembrolizumabConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2017-01-19AdcetrisBrentuximab VedotinNon-quantifiable
- 2016-12-15ImbruvicaIbrutinibNot proven: 3 of 3 patient groups
- 2016-12-15XalkoriCrizotinibConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2016-12-15OpdivoNivolumabNot proven: 2 of 2 patient groups
- 2016-12-15ImlygicTalimogen laherparepvecNot proven: 3 of 3 patient groups
- 2016-12-01HalavenEribulinConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2016-12-01EmplicitiElotuzumabMinor
- 2016-10-20OpdivoNivolumabConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2016-10-20OpdivoNivolumabConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2016-10-20GiotrifAfatinibNot proven: 2 of 2 patient groups
- 2016-10-20CyramzaRamucirumabMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2016-09-15ZydeligIdelalisibNon-quantifiable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2016-09-15TagrissoOsimertinibNot proven: 4 of 4 patient groups
- 2016-09-01CyramzaRamucirumabNot proven
- 2016-09-01CyramzaRamucirumabNot proven
- 2016-08-04ErivedgeVismodegibMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2016-07-21ImbruvicaIbrutinibConsiderable: 1 of 6 patient groupsNon-quantifiable: 2 of 6 patient groupsNot proven: 3 of 6 patient groups
- 2016-06-16XalkoriCrizotinibConsiderable
- 2016-06-02CosentyxSecukinumabNot proven
- 2016-06-02CotellicCobimetinibConsiderable
- 2016-05-19GilenyaFingolimodNot proven: 2 of 2 patient groups
- 2016-03-17Imnovid PomalidomidConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2016-03-17StivargaRegorafenibNot proven
- 2016-03-17MekinistTrametinibConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2016-03-17TafinlarDabrafenibConsiderable
- 2016-03-17FarydakPanobinostatNon-quantifiable
- 2016-02-18PerjetaPertuzumabNot proven
- 2016-02-04KeytrudaPembrolizumabConsiderable: 2 of 3 patient groupsNot proven: 1 of 3 patient groups
- 2016-02-04OpdivoNivolumabConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2016-01-07OpdivoNivolumabConsiderable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2016-01-07NulojixBelataceptConsiderable
- 2015-11-27CosentyxSecukinumabConsiderable: 1 of 2 patient groupsMinor: 1 of 2 patient groups
- 2015-11-05GiotrifAfatinibMajor: 1 of 5 patient groupsNot proven: 4 of 5 patient groups
- 2015-10-15JakaviRuxolitinibConsiderable
- 2015-10-01GilenyaFingolimodMinor
- 2015-08-06OtezlaApremilastNot proven: 2 of 2 patient groups
- 2015-06-18VargatefNintedanibMinor
- 2015-06-18XtandiEnzalutamidConsiderable
- 2015-03-19ZydeligIdelalisibNot proven
- 2015-02-19StivargaRegorafenibNot proven
- 2015-01-22HalavenEribulinConsiderable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2015-01-08EntyvioVedolizumabNot proven: 4 of 4 patient groups
- 2014-12-04SylvantSiltuximabNon-quantifiable
- 2014-11-06JakaviRuxolitinibConsiderable
- 2014-10-16TecfideraDimethylfumaratNot proven
- 2014-06-19KadcylaTrastuzumab EmtansinConsiderable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2014-06-05YervoyIpilimumabNot proven: 2 of 2 patient groups
- 2014-04-03TafinlarDabrafenibNot proven
- 2014-03-20AubagioTeriflunomidNot proven
- 2014-03-06ZelborafVemurafenibConsiderable
- 2014-02-20XtandiEnzalutamidConsiderable
- 2013-10-01PerjetaPertuzumabConsiderable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2013-08-15ZaltrapAfliberceptMinor
- 2013-07-04ZytigaAbirateronacetatConsiderable
- 2013-05-16PixuvriPixantronNot proven
- 2013-05-16AdcetrisBrentuximab VedotinNon-quantifiable: 3 of 3 patient groups
- 2013-05-02DacogenDecitabinMinor
- 2012-12-20TeysunoTegafur/Gimeracil/OteracilNot proven
- 2012-08-02YervoyIpilimumabConsiderable
- 2012-08-02BenlystaBelimumabConsiderable
- 2012-03-29ZytigaAbirateronacetatConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2012-03-29JevtanaCabazitaxelMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2012-03-15EsbrietPirfenidonNon-quantifiable
Data status: 2026-10-29